For example, a study by Lin and collaborators included 129 NSCLC participants with an ALK alteration (ALK‐positive or ALK+) and a further 577 patients from a Foundation Medicine dataset showed Variant 1 as most frequently detected at 43% compared to 40% with Variant 3 [17]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.